Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics
- 18 September 2012
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 109 (40), 16288-16293
- https://doi.org/10.1073/pnas.1210096109
Abstract
Mitochondrial dysfunctions cause numerous human disorders. A platform technology based on biodegradable polymers for carrying bioactive molecules to the mitochondrial matrix could be of enormous potential benefit in treating mitochondrial diseases. Here we report a rationally designed mitochondria-targeted polymeric nanoparticle (NP) system and its optimization for efficient delivery of various mitochondria-acting therapeutics by blending a targeted poly(d,l-lactic-co-glycolic acid)-block (PLGA-b)-poly(ethylene glycol) (PEG)-triphenylphosphonium (TPP) polymer (PLGA-b-PEG-TPP) with either nontargeted PLGA-b-PEG-OH or PLGA-COOH. An optimized formulation was identified through in vitro screening of a library of charge- and size-varied NPs, and mitochondrial uptake was studied by qualitative and quantitative investigations of cytosolic and mitochondrial fractions of cells treated with blended NPs composed of PLGA-b-PEG-TPP and a triblock copolymer containing a fluorescent quantum dot, PLGA-b-PEG-QD. The versatility of this platform was demonstrated by studying various mitochondria-acting therapeutics for different applications, including the mitochondria-targeting chemotherapeutics lonidamine and α-tocopheryl succinate for cancer, the mitochondrial antioxidant curcumin for Alzheimer's disease, and the mitochondrial uncoupler 2,4-dinitrophenol for obesity. These biomolecules were loaded into blended NPs with high loading efficiencies. Considering efficacy, the targeted PLGA-b-PEG-TPP NP provides a remarkable improvement in the drug therapeutic index for cancer, Alzheimer's disease, and obesity compared with the nontargeted construct or the therapeutics in their free form. This work represents the potential of a single, programmable NP platform for the diagnosis and targeted delivery of therapeutics for mitochondrial dysfunction-related diseases.Keywords
This publication has 32 references indexed in Scilit:
- Selective Uncoupling of Individual Mitochondria within a Cell Using a Mitochondria-Targeted Photoactivated ProtonophoreJournal of the American Chemical Society, 2011
- Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastomaProceedings of the National Academy of Sciences of the United States of America, 2011
- Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivoProceedings of the National Academy of Sciences of the United States of America, 2011
- Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapyProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeting mitochondria for cancer therapyNature Reviews Drug Discovery, 2010
- Small mitochondria-targeting molecules as anti-cancer agentsMolecular Aspects of Medicine, 2010
- Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: Hope from natural mitochondrial nutrientsAdvanced Drug Delivery Reviews, 2009
- Mitochondrial gateways to cancerMolecular Aspects of Medicine, 2009
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences of the United States of America, 2008
- Intracellular Distribution of TiO2−DNA Oligonucleotide Nanoconjugates Directed to Nucleolus and Mitochondria Indicates Sequence SpecificityNano Letters, 2007